FDA Rebuffs Alimera Diabetes Eye Treatment Over Concerns

Law360, New York (October 18, 2013, 5:19 PM EDT) -- U.S. regulators have rejected Alimera Sciences Inc.’s eye implant treatment for diabetes patients, citing concerns about its safety as well as potential issues at the facility where the implant is manufactured, the Georgia-based pharmaceutical firm said Friday.

The decision by the U.S. Food and Drug Administration came in response to Alimera’s New Drug Application for its Iluvien eye implant to treat diabetic macular edema, a condition that causes swelling within the eye, which diabetes patients may experience, the company said in a statement. The FDA sent...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.